Navigation Links
Amedica's Silicon Nitride Ceramic Bearing Technology Receives Prestigious HAP Paul Award for Use in Total Hip Arthroplasty
Date:10/10/2007

SALT LAKE CITY, Oct. 10 /PRNewswire/ -- Amedica Corporation, an orthopedic implants company focused on silicon nitride ceramic technologies, announced today that a paper it presented on the in-vitro testing and evaluation of its silicon nitride ceramic bearings for total hip arthroplasty won the HAP Paul Award from the International Society for Technology in Arthroplasty (ISTA). The prestigious HAP Paul Award, which was presented to Amedica at ISTA's 20th Annual Congress, held October 4 - 6, 2007, in Paris, France, is given for outstanding research in new technology for joint replacements.

The award-winning research paper, "In Vitro Performance of Silicon Nitride Ceramic in Total Hip Bearings," will be published by ISTA as a special article in the Journal of Arthroplasty. The paper demonstrates that Amedica's MC2(TM) silicon nitride based ceramic bearings, being developed for reconstructive hip, knee and spine implants, have the combination of strength, toughness and wear resistance characteristics that may overcome the limitations of currently available bearings.

The paper was authored by a team led by Ashok Khandkar, Ph.D., and included B. Sonny Bal, MD, University of Missouri, Columbia; Dr. Aaron A. Hofmann MD; University of Utah; Dr. Ian C. Clarke, Ph.D., Loma Linda University; Dr. Alan Lakshminarayanan, Ph.D., Amedica; and Mohamed N. Rahaman, Ph.D., University of Missouri-Rolla.

The team of collaborators compared the fracture strength and in-vitro wear characteristics using hip simulators of Amedica's Micro-composite Ceramic, or MC2, bearings with current state-of-the-art bearings. The data presented at ISTA's Annual Congress demonstrated that the silicon nitride femoral heads had substantially greater burst strength than similar 28 mm femoral heads made using the strongest commercially available ceramic.

"We are delighted and honored to win the HAP Paul Award for our work," said Ashok Khandkar, Ph.D., CEO of Amedica Corporation. "This paper demonstrates the inherent strength and wear resistance advantages of silicon nitride ceramics compared with the current generation of ceramic orthopedic implants. We are pleased that a group of our peers has selected our research on silicon nitride ceramic and recognized the important potential of this material for total hip arthroplasty. Importantly, we believe independent recognition such as this award, will increase awareness of silicon nitride and support its future use in orthopedic applications such as ceramic bearings for joint replacement."

About Amedica

Amedica Corporation is an emerging orthopedic implants company focused on using its ceramics technologies to develop and commercialize a broad range of innovative, high-performance spine and joint implants for the growing orthopedic device market. Its products under development include reconstructive spine, hip and knee implants that may represent a new standard of care in total joint implants based on superior durability, performance and safety.

Contact:

Ashok C. Khandkar

Chief Executive Officer

(801) 583-5100

Email: ak@amedicacorp.com

http://www.amedicacorp.com


'/>"/>
SOURCE Amedica Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Silicon eye implants
2. Artificial silicon retina
3. Implantable devices to be powered by organosilicon compounds in the future
4. Silicone Rubber Flap Restore Speech
5. Silicone Implants Make No Significant Difference To Breast Cancer Survivors
6. Potentially Dangerous levels of Platinum Found in Women with Silicone Gel Breast Implants
7. Silicone Leaks Seen Among Women with Breast Implants
8. Canadian Regulators allow Silicone Breast Implants in Market
9. FDA gives the green signal for silicone breast implants
10. School atmosphere have some bearing on bad habits in children
11. Vitamin B: Vital for Women During Child-bearing Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: